Surveillance as a safe and effective option for treatment of stage I seminoma
Open Access
- 5 September 2023
- journal article
- research article
- Published by PAGEPress Publications in Archivio Italiano di Urologia e Andrologia
- Vol. 95 (3) , 11513
Abstract
Introduction: Stage I seminoma has a very good prognosis, yet approximately 15% have subclinical metastatic disease and will relapse after orchidectomy alone. Several management approaches have been investigated. We aimed to evaluate the clinical outcomes of real-world patients with stage I seminoma, analysing prognostic factors influencing treatment choice and oncological outcomes. Methods: Retrospective, single institution study, with 55 patients diagnosed with clinical stage I seminoma between 2007 and 2020. Selected patients were analysed regarding three management approaches - surveillance, adjuvant radiotherapy and adjuvant carboplatin AUC7. Overall survival and progression-free survival outcomes were analysed. Predictors of treatment choice were determined, and predictors of recurrence were analysed in patients on active surveillance. Results: The median follow-up time was 91 months (13-165). Overall survival at 10 years was 98.2%. Stage I seminoma patients had a 1-, 3- and 10-year progression free survival of 98%, 94% and 89%, respectively. Three-year progression free survival was 92.0% for those on active surveillance (IC95%, 91.5-92.5%), 95.2% for carboplatin (IC95%, 94.8-95.6%) and 100% for those on adjuvant radiotherapy (p > 0.05). All relapses on active surveillance protocols occurred during the first 24 months. Overall, 43% of patients who underwent adjuvant treatment reported adverse effects of therapy, with higher incidence on radiotherapy group (63%). Conclusions: Stage I seminoma have excellent prognosis, high cure rates, and low treatment-associated morbidity. Active surveillance is a safe modality when applied to selected patients. Adjuvant radiotherapy and adjuvant chemotherapy with carboplatin show similar results, with fewer adverse effects on chemotherapy arm.Keywords
This publication has 22 references indexed in Scilit:
- Patterns of Relapse in Patients With Clinical Stage I Testicular Cancer Managed With Active SurveillanceJournal of Clinical Oncology, 2015
- Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG)Annals of Oncology, 2014
- Risk-Adapted Treatment in Clinical Stage I Testicular Seminoma: The Third Spanish Germ Cell Cancer Group StudyJournal of Clinical Oncology, 2011
- Randomized Trial of Carboplatin Versus Radiotherapy for Stage I Seminoma: Mature Results on Relapse and Contralateral Testis Cancer Rates in MRC TE19/EORTC 30982 Study (ISRCTN27163214)Journal of Clinical Oncology, 2011
- Management of Stage I Seminomatous Testicular Cancer: a Systematic ReviewClinical Oncology, 2010
- A comprehensive systematic review of testicular germ cell tumor surveillanceCritical Reviews in Oncology/Hematology, 2007
- Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trialThe Lancet, 2005
- The changing presentation of germ cell tumours of the testis between 1983 and 2002BJU International, 2005
- Results of a policy of surveillance in stage I testicular seminomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1993
- Stage I testicular seminoma: rationale for postorchiectomy radiation therapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1987